Due to the funding or execution of studies by industry stakeholders and disagreements over methodological approaches, establishing and maintaining trust has been a major ongoing concern in HEOR studies. To this end, attempts have been made to standardize or improve methods, establish ethical codes of practice, and improve transparency in study reporting. Recently, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced the publication of a report, produced by the Real-World Evidence (RWE) Transparency Initiative, arguing for routine registration of hypothesis-evaluating RWE studies of treatment effectiveness. The publication embodies the Initiative’s larger aim of increasing transparency and building trust in the use of secondary data in healthcare research. Read more here.